WHO essential medicines for children 2011–2019: age-appropriateness of enteral formulations
- 3 September 2021
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 107 (4), 317-322
- https://doi.org/10.1136/archdischild-2021-321831
Abstract
Introduction The WHO Essential Medicine List for children (EMLc) is used for promoting access to medicines. The age-appropriateness of enteral (oral and rectal) formulations for children depend on their adaptability/flexibility to allow age-related or weight-related doses to be administered/prescribed and the child’s ability to swallow, as appropriate. There is scant information on the age-appropriateness of essential enteral medicines for children. Objective To evaluate the age-appropriateness of enteral essential medicines. Materials and methods Age-appropriateness of all enteral formulations indicated and recommended in the EMLc 3rd to 7th (2011–2019) editions were determined by assessing swallowability and/or dose adaptability for children under 12 years, stratified into five age groups. Results Enteral formulations in the EMLc were more age-appropriate for older children aged 6–11 years than for younger children. In the 3rd edition, for older children, 77%, n=342, of formulations were age-appropriate. For younger children, age-appropriateness decreased with age group: 34% in those aged 3–5 years, 30% in those aged 1–2 years, 22% among those aged 28 days to 11 months and 15% in those aged 0–27 days. Overall, similar proportions were found for the 7th edition. In contrast, the majority of medicines in the 7th list were age-appropriate in targeted diseases like HIV and tuberculosis. Conclusion Most recommended enteral essential medicines in EMLc 2011 and 2019 were not age-appropriate for children <6 years. Medicines which are not age-appropriate must be manipulated before administration, leading to potential issues of safety and efficacy. Evaluation of the age-appropriateness of formulations for medicines to be included in EMLc could improve access to better medicines for children in the future.Keywords
Funding Information
- European Union (261060, FP7/2007-2013)
This publication has 21 references indexed in Scilit:
- Formulations for children: problems and solutionsBritish Journal of Clinical Pharmacology, 2015
- Solid oral forms availability in children: a cost saving investigationBritish Journal of Clinical Pharmacology, 2014
- Paediatric drug development: The impact of evolving regulationsAdvanced Drug Delivery Reviews, 2014
- Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidenceBMC Pediatrics, 2013
- A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms – An application for paediatric dosage form selectionInternational Journal of Pharmaceutics, 2012
- Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over studyArchives of Disease in Childhood, 2012
- Specific aspects of gastro-intestinal transit in children for drug delivery designInternational Journal of Pharmaceutics, 2010
- Minitablets: New Modality to Deliver Medicines to Preschool-Aged ChildrenPEDIATRICS, 2009
- Developing paediatric medicines: identifying the needs and recognizing the challengesJournal of Pharmacy and Pharmacology, 2007
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenThe New England Journal of Medicine, 2003